{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Jyong Biotech Ltd."},"Symbol":{"label":"Symbol","value":"MENS"},"Address":{"label":"Address","value":"23F-3, NO. 95,SECTION 1,XINTAI 5TH ROAD,XIZHI DISTRICT, NEW TAIPEI CITY, 221, Taiwan"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan. Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis."},"CompanyUrl":{"label":"Company Url","value":null}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}